BioSpace News Archive

Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share

Viela Bio announced it will host a webcast and conference call on Tuesday, November 10, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 financial results and program highlights.

Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET.

Orchard Therapeutics, a global gene therapy leader, announced that the company will webcast a virtual R&D event ‘New Horizons in Gene Therapy’ on Friday, November 13, 2020 from 9:00 a.m. to 11:00 a.m. ET.

Recro Pharma, Inc. announced that it will report third quarter 2020 financial results on Monday, November 9, 2020.

Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, announced that it will report third quarter 2020 financial results on Monday, November 9, 2020.

KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.

CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced that it has received the first tranche of $4 million of a committed financing of $10 million, after original issue discounts, through the issuance of convertible notes (the “Notes”).

Amplifire , an eLearning company, announced today the award of an additional patent by the United States Patent Office. Amplifire holds patents issued in the US, EU, Australia , Canada , Japan , South Korea , and other countries and jurisdictions worldwide. The new patent is titled Display and Report Generation Platform for Te

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.